Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.

Introduction: Multidrug therapy for leprosy is currently done with dapsone, clofazimine and rifampicin. Dapsone is known to cause hemolytic anemia (HA) and this adverse event during MDT seems to be more frequent than reported. The aim of this report is to discuss and grade HA due to dapsone during MDT treatment for leprosy.

Adverse effects from multi-drug therapy in leprosy: a Brazilian study.

Introduction: The WHO MDT for leprosy treatment was officially introduced in Brazil in 1991 and comprises three drugs: dapsone, rifampicin and clofazimine. There are few good studies on the frequency of side-effects attributable to MDT in Brazil.

Methods: A retrospective and descriptive study carried out in a LCP in Vitória, State of Espirito Santo, Brazil.